Moffat F L, Gilas T, Calhoun K, Falk M, Dalfen R, Rotstein L E, Makowka L, Howard V, Laing D, Venturi D
Cancer. 1985 Mar 15;55(6):1291-5. doi: 10.1002/1097-0142(19850315)55:6<1291::aid-cncr2820550623>3.0.co;2-g.
The authors report on 178 patients with unresectable hepatic tumors who have been treated with 1 to 25 (median, 6) courses of radiofrequency hyperthermia (RFHT) and chemotherapy. In 137 patients, the hepatic tumors consisted of metastases from colorectal adenocarcinomas. For patients who had no previous therapy and who had colorectal metastases with no extraheptic disease, cumulative survival at 52 weeks' follow-up was 80.5% and partial tumor regression was seen in 78.4%. Among the 69 patients who previously had conventional treatment for their hepatic disease, partial regression was seen in 43.5%. We are no longer monitoring tumor core temperature routinely, as the invasive methods currently in use yield irreproducible results; the risks to the patient cannot be justified in view of the questionable relevance of the data obtained. A prospective randomized study of systemic chemotherapy with or without RFHT in patients with colorectal hepatic metastases is in progress.
作者报告了178例无法切除的肝肿瘤患者,这些患者接受了1至25个疗程(中位数为6个疗程)的射频热疗(RFHT)和化疗。137例患者的肝肿瘤为大肠腺癌转移瘤。对于未曾接受过治疗且有大肠转移瘤且无肝外疾病的患者,在52周随访时的累积生存率为80.5%,78.4%的患者出现部分肿瘤消退。在69例先前已对其肝病进行过常规治疗的患者中,43.5%的患者出现部分消退。我们不再常规监测肿瘤核心温度,因为目前使用的侵入性方法产生的结果不可重复;鉴于所获得数据的相关性存疑,对患者的风险是不合理的。一项关于结直肠癌肝转移患者接受全身化疗联合或不联合RFHT的前瞻性随机研究正在进行中。